시장보고서

상품코드

1701316

폰다파리눅스(Fondaparinux) 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Fondaparinux Market Size, Share & Trends Analysis Report By Type (Deep Vein Thrombosis), By Product (Branded, Generic), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 03월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

폰다파리눅스 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계의 폰다파리눅스 시장 규모는 2030년까지 9억 9,090만 달러에 달할 것으로 추정되며, 2025-2030년에 걸쳐 6.3%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

폰다파리눅스는 주로 무릎 관절 치환술과 고관절 치환술에 사용됩니다. 활성 분자는 제조가 매우 복잡하기 때문에 2011년까지 낮은 제네릭 경쟁에 직면했습니다.

폰다파리눅스는 항응고제로 사용되며, 저분자 헤파린에 비해 생존율의 향상을 나타내고 있습니다.

특허 기술을 통해 분자를 생산하기위한 지적 재산권(IPR)을 얻기 위한 주요 진출기업 간의 협력 증가는 성장을 가속할 것으로 예상됩니다. 2016년 7월, Dr. Reddy's Laboratories Ltd.는 Alchemia Ltd.와 폰다파리눅스 나트륨의 IPR을 1,750만 달러로 구매하는 계약을 체결했습니다. 2014년 9월, Mylan NV는 폰다파리눅스 나트륨의 선발품과 후발품을 아스펜·세계사에서 2억 2,500만 달러로 구입했습니다.

폰다파리눅스 시장 보고서 하이라이트

제네릭 의약품은 2024년에 52.1%의 최대 매출 점유율을 차지했고 예측 기간 동안도 그 우위성을 유지할 것으로 예상됩니다.
심부정맥 혈전증(DVT) 부문은 2024년에 시장의 주요 점유율을 차지했습니다.
2024년, 병원 약국이 폰다파리눅스의 주요 유통 채널에 부상했습니다.
북미의 폰다파리눅스 시장은 세계 시장을 독점해, 2024년에는 37.6%의 최대 매출 점유율을 차지했습니다.

지역별 시장 점유율 분석(2024년, 2030년)
지역별 시장 대시보드
시장 규모, 예측 동향 분석(2018-2030년)
북미
- 국가별(2018-2030년)
- 미국
- 캐나다
- 멕시코
유럽
- 국가별(2018-2030년)
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 국가별(2018-2030년)
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 국가별(2018-2030년)
- 브라질
- 아르헨티나
중동 및 아프리카
- 국가별(2018-2030년)
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일/상장 기업
- Abbott Laboratories Inc.
- Alchemia Limited
- Apotex Inc.
- GSK plc
- Lupin Pharmaceuticals, Inc
- ScinoPharm Taiwan Ltd
- Dr. Reddy's Laboratories Ltd.
- Bayer Healthcare AG
- GlaxoSmithKline
- Boehringer Ingelheim
- Sanofi
- WisMed
- Kaifeng
- Mylan

KTH 25.04.25

Fondaparinux Market Growth & Trends:

The global fondaparinux market size is estimated to reach USD 990.9 million by 2030, registering to grow at a CAGR of 6.3% from 2025 to 2030 according to a new report by Grand View Research, Inc. Fondaparinux is majorly used during knee and hip replacement surgeries. Arixtra, manufactured by GSK group of companies is the branded drug of Fondaparinux. The drug witnessed patent expiry in 2002. As the active molecule is highly complex to manufacture, it faced low generic competition until 2011. Generic manufacturer companies, such as Alchemia Ltd. and Apotex, Inc., received the Abbreviated New Drug Application approval in 2011 and instantly started the production of generic drugs.

Fondaparinux is used as an anticoagulant and shows improved survival compared with low-molecular-weight heparin. It is used for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is administered subcutaneously. Moreover, Fondaparinux lowers the risk of ischemic events

The increasing collaboration between the key players for acquiring the Intellectual Property Rights (IPRs) in order to manufacture the molecule through patented technology is expected to drive growth. For instance, in July 2016 Dr. Reddy's Laboratories Ltd. entered into an agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium for USD 17.5 million. In September 2014, Mylan N.V. purchased branded and generic versions of fondaparinux sodium from Aspen Global, Inc. for USD 225 million. The deal gave Mylan N.V. access to one of the two generics indicated for the treatment of PE.

Fondaparinux Market Report Highlights:

The generic segment accounted for the largest revenue share of 52.1% in 2024 and is expected to maintain its dominance during the forecast period.
The Deep Vein Thrombosis (DVT) segment accounted for a leading share of the market in 2024.
Hospital pharmacies emerged as the leading distribution channel for fondaparinux in 2024
North America fondaparinux market dominated the global market and accounted for the largest revenue share of 37.6% in 2024

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Product
- 1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Fondaparinux Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Fondaparinux Market: Type Business Analysis

4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Deep Vein Thrombosis
- 4.4.1. Deep Vein Thrombosis Market, 2018 - 2030 (USD Million)
4.5. Pulmonary Embolism
- 4.5.1. Pulmonary Embolism Market, 2018 - 2030 (USD Million)

Chapter 5. Fondaparinux Market: Product Business Analysis

5.1. Product Market Share, 2024 & 2030
5.2. Product Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
5.4. Branded
- 5.4.1. Branded Market, 2018 - 2030 (USD Million)
5.5. Generic
- 5.5.1. Generic Market, 2018 - 2030 (USD Million)

Chapter 6. Fondaparinux Market: Distribution Channel Business Analysis

6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Fondaparinux Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
- 7.4.1. North America Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework
  - 7.4.2.3. Competitive Insights
  - 7.4.2.4. U.S. Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework
  - 7.4.3.3. Competitive Insights
  - 7.4.3.4. Canada Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Regulatory Framework
  - 7.4.4.3. Competitive Insights
  - 7.4.4.4. Mexico Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
- 7.5.1. Europe Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework
  - 7.5.2.3. Competitive Insights
  - 7.5.2.4. UK Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework
  - 7.5.3.3. Competitive Insights
  - 7.5.3.4. Germany Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework
  - 7.5.4.3. Competitive Insights
  - 7.5.4.4. France Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework
  - 7.5.5.3. Competitive Insights
  - 7.5.5.4. Italy Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework
  - 7.5.6.3. Competitive Insights
  - 7.5.6.4. Spain Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework
  - 7.5.7.3. Competitive Insights
  - 7.5.7.4. Denmark Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework
  - 7.5.8.3. Competitive Insights
  - 7.5.8.4. Sweden Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Regulatory Framework
  - 7.5.9.3. Competitive Insights
  - 7.5.9.4. Norway Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework
  - 7.6.2.3. Competitive Insights
  - 7.6.2.4. Japan Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework
  - 7.6.3.3. Competitive Insights
  - 7.6.3.4. China Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework
  - 7.6.4.3. Competitive Insights
  - 7.6.4.4. India Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework
  - 7.6.5.3. Competitive Insights
  - 7.6.5.4. Australia Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework
  - 7.6.6.3. Competitive Insights
  - 7.6.6.4. South Korea Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Regulatory Framework
  - 7.6.7.3. Competitive Insights
  - 7.6.7.4. Thailand Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework
  - 7.7.2.3. Competitive Insights
  - 7.7.2.4. Brazil Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework
  - 7.7.3.3. Competitive Insights
  - 7.7.3.4. Argentina Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
- 7.8.1. MEA Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework
  - 7.8.2.3. Competitive Insights
  - 7.8.2.4. South Africa Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework
  - 7.8.3.3. Competitive Insights
  - 7.8.3.4. Saudi Arabia Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework
  - 7.8.4.3. Competitive Insights
  - 7.8.4.4. UAE Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Regulatory Framework
  - 7.8.5.3. Competitive Insights
  - 7.8.5.4. Kuwait Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Abbott Laboratories Inc.
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Alchemia Limited
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Apotex Inc.
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. GSK plc
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Lupin Pharmaceuticals, Inc
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. ScinoPharm Taiwan Ltd
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Dr. Reddy's Laboratories Ltd.
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives.
- 8.5.8. Bayer Healthcare AG
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. GlaxoSmithKline
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. Boehringer Ingelheim
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic Initiatives
- 8.5.11. Sanofi
  - 8.5.11.1. Overview
  - 8.5.11.2. Financial Performance
  - 8.5.11.3. Product Benchmarking
  - 8.5.11.4. Strategic Initiatives
- 8.5.12. WisMed
  - 8.5.12.1. Overview
  - 8.5.12.2. Financial Performance
  - 8.5.12.3. Product Benchmarking
  - 8.5.12.4. Strategic Initiatives
- 8.5.13. Kaifeng
  - 8.5.13.1. Overview
  - 8.5.13.2. Financial Performance
  - 8.5.13.3. Product Benchmarking
  - 8.5.13.4. Strategic Initiatives
- 8.5.14. Mylan
  - 8.5.14.1. Overview
  - 8.5.14.2. Financial Performance
  - 8.5.14.3. Product Benchmarking
  - 8.5.14.4. Strategic Initiatives

폰다파리눅스(Fondaparinux) 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Fondaparinux Market Size, Share & Trends Analysis Report By Type (Deep Vein Thrombosis), By Product (Branded, Generic), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

폰다파리눅스 시장 성장과 동향

폰다파리눅스 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 폰다파리눅스 시장 변수, 동향, 범위

제4장 폰다파리눅스 시장 : 유형 비즈니스 분석

제5장 폰다파리눅스 시장 : 제품 비즈니스 분석

제6장 폰다파리눅스 시장 : 유통 채널 비즈니스 분석

제7장 폰다파리눅스 시장 : 지역별, 추정·동향 분석